Back to top
more

ProDex (PDEX)

(Delayed Data from NSDQ)

$33.81 USD

33.81
44,181

+1.19 (3.65%)

Updated Sep 16, 2025 04:00 PM ET

After-Market: $33.68 -0.13 (-0.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (76 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Pro-Dex, Inc. (PDEX) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

ProDex (PDEX) delivered earnings and revenue surprises of -23.40% and -2.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Cooper Companies (COO) Q3 Earnings Beat Estimates

by Zacks Equity Research

The Cooper Companies (COO) delivered earnings and revenue surprises of +2.80% and -0.50%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -41.30% and +0.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Accuray (ARAY) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of -100.00% and +2.49%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardinal Health (CAH) Tops Q4 Earnings Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of +2.46% and -0.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dentsply International (XRAY) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of +4.00% and +0.31%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in ProDex (PDEX): Can Its 8.2% Jump Turn into More Strength?

by Zacks Equity Research

ProDex (PDEX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

New Strong Buy Stocks for July 1st

by Zacks Equity Research

NGD, GECC, MITSY, CWEN and PDEX have been added to the Zacks Rank #1 (Strong Buy) List on July 1, 2025.

Zacks Equity Research

Best Value Stocks to Buy for July 1st

by Zacks Equity Research

MITSY, NGD and PDEX made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 1, 2025.

Zacks Equity Research

Here is Why Growth Investors Should Buy ProDex (PDEX) Now

by Zacks Equity Research

ProDex (PDEX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

ProDex (PDEX) Upgraded to Buy: Here's Why

by Zacks Equity Research

ProDex (PDEX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Pro-Dex, Inc. (PDEX) Q3 Earnings Surpass Estimates

by Zacks Equity Research

ProDex (PDEX) delivered earnings and revenue surprises of 108.51% and 1.62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?

by Zacks Equity Research

ProDex (PDEX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Zacks Equity Research

ProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

ProDex (PDEX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

ProDex (PDEX) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

ProDex (PDEX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Pro-Dex, Inc. (PDEX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ProDex (PDEX) delivered earnings and revenue surprises of 60.53% and 21.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

All You Need to Know About ProDex (PDEX) Rating Upgrade to Buy

by Zacks Equity Research

ProDex (PDEX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

ProDex (PDEX) Moves 23.0% Higher: Will This Strength Last?

by Zacks Equity Research

ProDex (PDEX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Pro-Dex Stock Skyrockets Over the Past Year: A Must Buy?

by Zacks Equity Research

Investors can consider investing in PDEX right now as the stock has done extremely well through 2024 and its prospects continue to shine.

Zacks Equity Research

Best Momentum Stocks to Buy for January 6th

by Zacks Equity Research

NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.

Zacks Equity Research

New Strong Buy Stocks for January 6th

by Zacks Equity Research

ALK, AHT, NRXP, PDEX and EGAN have been added to the Zacks Rank #1 (Strong Buy) List on January 6, 2024.

Zacks Equity Research

Merit Medical (MMSI) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 7.50% and 1.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pro-Dex Q4 Earnings Rise Y/Y, Sales Surge on Customer Growth

by Zacks Equity Research

PDEX sees EPS rise to 46 cents in fiscal Q4 alongside a 41% surge in sales to $15 million, fueled by strategic operational efficiencies and key customer growth.

Debasmita Chatterjee headshot

Zacks Initiates Coverage of Pro-Dex With Outperform Recommendation

by Debasmita Chatterjee

Discover why Zacks rates Pro-Dex as "Outperform," being the first on Wall Street to initiate coverage on the stock. Explore its strong sales growth, strategic expansion, key alliances, financial stability and robust customer relationships.